Egalet presented data from a harm reduction model which showed that replacing morphine extended-release products that are non-abuse-deterrent with Arymo ER (morphine sulfate) extended-release tablets, could result in decreased healthcare utilization and death. The full findings were announced at the 36th American Pain Society (APS) annual meeting.
The model, which simulated various scenarios of replacing the non-abuse-deterrent formulations of morphine with Arymo ER over a 5 year period, was used to investigate the extent of the potential to reduce opioid abuse, misuse, and abuse-related healthcare utilization. Using inputs such as diagnosed opioid abuse prevalence from claims data, researchers assessed the potential impact of Arymo ER on abuse-related healthcare utilization.
The findings showed that initiating Arymo ER may be tied to less abuse-related emergency department visits, outpatient visits, hospitalizations, substance abuse treatments, injection-related diseases, and deaths. The study authors added that the true extent of harm reduction, however, will not be determined until Arymo ER has been marketed for a longer period of time and real-world data is collected on the reduction of misuse and abuse.
Arymo ER, an opioid agonist, is available as 15mg, 30mg, and 60mg extended-release tablets in 100-count bottles.
For more information call (800) 518-1084 or visit Egalet.com.